CLOs on the Move

Richland Public Health

www.richlandhealth.org

 
Richland Public Health is the lead agency in the event of a county emergency of a biological nature, either through an infectious disease or terrorist threat.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

SironaHealth

SironaHealth is a South Portland, ME-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Turnaround Team

The Turnaround Team is a Westfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

My Brother's Keeper

My Brother's Keeper is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrative Emergency Services

Integrative Emergency Services (IES) is a healthcare company that partners with Texas hospitals to provide the best patient encounter in emergency care. IES is transforming the way healthcare is practiced across the continuum of care and furthering the...

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.